美通社

2024-08-13 09:03

Chang Gung Cancer Proton Therapy Achieves Breakthrough

Research Confirms Effective Control of Large Liver Cancer, Doubling Survival Time

Published in the International Journal of Radiation Oncology

TAOYUAN, Aug. 13, 2024 /PRNewswire/ -- With cancer incidence on the rise, proton therapy has emerged as one of the most powerful tools in cancer treatment. Chang Gung Memorial Hospital, Linkou, the first on the island to introduce proton therapy, has treated over 5,000 cancer patients with remarkable success. In a parallel research endeavor, the hospital's team found liver cancer patients treated with proton therapy achieve better tumor control and double the survival time compared to traditional X-ray radiation therapy, with fewer side effects. The findings were published in the March 2024 edition of the International Journal of Radiation Oncology, Biology, Physics, the leading international journal in the field of radiation oncology

The doctors involved in the project explained that proton therapy serves as "surgical strike" deep within the body, only releasing significant radiation energy when the protons reach the target tumor and destroying it with utmost precision while minimizing damage to nearby normal tissues and reducing side effects. The pinpoint accuracy stands apart from traditional X-ray radiotherapy, which often incurs greater collateral damage. By allowing for safer dose escalation, proton therapy optimizes patient outcomes and maintains their quality of life. 

The hospital conducted a four-year follow-up study on 159 patients with extensive liver cancer undergoing either proton therapy or conventional X-ray radiotherapy. The results showed that the two-year local tumor control rate for proton therapy was 89%, significantly surpassing the 34% achieved with traditional X-ray. Additionally, the median survival time for those treated with proton therapy was 19 months—more than double the 8 months observed with X-ray treatments. Moreover, the incidence of liver failure, upper gastrointestinal bleeding, or severe lymphocytopenia was significantly lower in the proton therapy group. 

While many studies have confirmed the efficacy of proton therapy, larger-scale research on its effectiveness for tumors larger than 5 cm or previously intractable large liver cancers has yet to be conducted. Chang Gung Memorial Hospital, Linkou, advises patients to obtain comprehensive professional consultation prior to treatment to ensure they receive the most optimal care. 

Chang Gung Memorial Hospital, Linkou is one of the largest proton radiation therapy centers in Asia, with patients from over 30 countries, including Malaysia, Singapore, and Vietnam. The hospital houses an International Medical Center, providing professional medical consultations, second opinions, medical arrangements, and coordinated multidisciplinary medical services, including surgery, chemotherapy, immunotherapy, and traditional Chinese medicine adjustments to offer comprehensive care for cancer patients. 

Proton therapy treats a variety of cancers, including brain tumors, nasopharyngeal carcinoma, lung, breast, and liver cancers. It targets tumors with precision, minimizing damage to surrounding healthy tissue compared to conventional X-ray radiation therapy. This method reduces radiation-induced side effects and is particularly effective in treating extensive liver cancers, enhancing patients' survival prospects. (Courtesy of Chang Gung Memorial Hospital, Linkou)
Proton therapy treats a variety of cancers, including brain tumors, nasopharyngeal carcinoma, lung, breast, and liver cancers. It targets tumors with precision, minimizing damage to surrounding healthy tissue compared to conventional X-ray radiation therapy. This method reduces radiation-induced side effects and is particularly effective in treating extensive liver cancers, enhancing patients' survival prospects. (Courtesy of Chang Gung Memorial Hospital, Linkou)

CONTACT: IMC CGMH, isc@cgmh.org.tw

source: Chang Gung Memorial Hospital, Linkou

【你點睇?】財政預算案展開公眾諮詢,學者倡問責官員減薪並削減公務員編制,你是否認同? ► 立即投票

人氣文章
最近7天
1
高息定存 | 滙豐3個月港元存息高達3.8厘,6個月3.55厘
2
高息定存 | 一周高息合集,信銀國際3個月有3.88厘
3
高息定存 | 工銀亞洲新推38日4.08厘,集友3個月加至3.7厘
4
高息定存 | 一周高息合集,大新3個月最高4.1厘,華僑及信銀國際見4厘
5
高息定存 | 銀行高息搶存,東亞上調3個月定存息至3.9厘,花旗加至3.7厘
6
MPF股票基金大檢閱 人均五年賺超逾一成半 友邦升幅最多 50萬本金可賺逾18萬元
7
【FOCUS】豪賭折射威權脆弱,尹錫悅去留牽動地緣
8
基建債券 | 基建債券明開售保底息3.5厘,專家建議抽幾多手? 一文看清認購優惠!
9
港股 | 蕭猷華:恒指料反彈,短線看幾多?
10
南韓戒嚴 | 韓國防部長金龍顯辭職
11
高息定存 | 華僑推3個月快閃達4厘,信銀國際全線升3個月存息
12
呂志和喪禮|呂志和香港殯儀館設靈,中聯辦鄭雁雄、李家超、陳啟宗等人到場(圖集)
13
局長換人 | 國務院:免去林世雄、楊潤雄局長職務,任命陳美寶、羅淑佩接任(楊潤雄facebook回應)
14
一周部署 | 非農數據前美股料穩,OPEC+會議全球矚目
15
熊貓經濟 | 2500隻大熊貓雕塑抵港,周六起星光大道等地展出
16
建銀國際料明年恒指先低後高,波動區間18000至23000點
17
傾力救市 | 華爾街大行預計中國明年降息幅度將達十年來最大
18
高息定存 | 10萬元起存3個月最高3.9厘,渣打加至3.6厘
19
港股 | 蕭猷華:關注中央經濟工作會議,美團股價落後
20
高息定存 | 建行亞洲上調3個月存息至3.85厘,富邦3.8厘
21
高息定存 | 華僑銀行208日定存年息高達3.8厘
22
基建債券 | 認購額178.5億首未足額,發言人:受減息步伐影響
23
順豐上市 | 順豐招股溫和料見增長瓶頸 A股提前派息慶功欠誠意
24
內險股 | 金監總局促保險業轉變發展模式,內險股股價持續受壓未屆吸納時?
25
李家超下周率工商界代表團訪大灣區,促進經貿合作
26
神州經脈 | 深圳恢復赴港一簽多行,本月買斷式逆回購8000億
27
NVIDIA | 陳茂波與黃仁勳等到深水埗品嚐地道小炒,交流創科發展經驗
28
神州經脈 | 政治局會議定調明年貨幣政策適度寬鬆,CPI遜預期
29
港股 | 午市前瞻 | 金監局新指示恒指跌幅擴大 百度優勢大惟變現需時
30
特首述職|習近平讚揚李家超務實進取,中央全力支持帶領各界改革
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

【etnet 30周年】多重慶祝活動一浪接一浪,好禮連環賞!

【etnet30周年連環賞】睇住賞Maxcare美天復康寶(升級版) (價值HK$1,680)

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

回顧24 展望25

大國博弈

貨幣攻略

說說心理話

聖誕新年特輯

Watche Trends 2024

北上食買玩

Artcation

秋冬養生食療

消委會報告

山今養生智慧

輕鬆護老